Economic impact of using maternal plasma cell-free DNA testing to guide further workup in recurrent pregnancy loss

Siyang Peng, Sucheta Bhatt, Antoni Borrell, Yuval Yaron*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: We have previously demonstrated that maternal-plasma cell-free DNA (cfDNA)-testing can detect chromosomal anomalies in recurrent pregnancy loss (RPL) with 81.8% sensitivity and 90.3% specificity. Here we assess whether this is cost effective in guiding further workup in RPLs. Method: A decision-analytic model was developed to compare the cost of various RPL management pathways: (1) current American Society for Reproductive Medicine (ASRM) RPL workup; (2) microarray or karyotyping analysis of products of conception (POCs) and RPL workup only for euploid cases; and (3) cfDNA testing and RPL workup only for euploid cases. Sample accessibility, failure rates, and sensitivity were specified for each test. Costs of sample collection, genetic tests, and RPL workup were considered. Analysis outcomes included detection rate of chromosomal anomaly and cost per patient tested. Results: In comparison to existing cytogenetic testing on POCs, cfDNA testing pathway allowed for better sample accessibility with a lower cost per patient. In addition, using cfDNA to guide further workup significantly increases the number of causative fetal chromosome anomalies detected, reducing the number of patients undergoing unnecessary workup resulting in an overall cost savings. Conclusion: Our study showed that inclusion of cfDNA testing is a cost-effective approach to guide RPL workup.

Original languageEnglish
Pages (from-to)1215-1221
Number of pages7
JournalPrenatal Diagnosis
Volume41
Issue number10
DOIs
StatePublished - Sep 2021

Fingerprint

Dive into the research topics of 'Economic impact of using maternal plasma cell-free DNA testing to guide further workup in recurrent pregnancy loss'. Together they form a unique fingerprint.

Cite this